title: Combination therapy of S-1 and CDDP for patients with colorectal cancer.
abstract: OBJECTIVE
  We evaluate the feasibility and efficacy of S-1 in combination with cisplatin (CDDP) for patients with colorectal cancer.
  
  
  METHODS
  A total of 52 patients with advanced or recurrent colorectal cancer were included. S-1 was given orally twice daily for 21 days and CDDP 30 mg/m(2) on day 1 and 8, followed by a 2-week period of no treatment.
  
  
  RESULTS
  Tumor responses among patients included 18 PR, 12 SD, and 16 PD (n = 46). The overall response rate was 36.4% (18/46). The response rate of the patients with prior chemotherapy was 22.2% (4/18) and 50.0% (12/24) among the patients who had no prior therapy. The median survival periods were 555 days and the median progression free survival periods were 183 days, respectively. S-1 in combination with CDDP shows promising activity with acceptable toxicities against colorectal cancer.
  
  
  CONCLUSIONS
  A combination of S-1 and CDDP could be a standard therapy for treating colorectal carcinoma.
authors.affiliation: Institute of Gastroenterology, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjukuku, Tokyo 162-8666, Japan. uchida@hosp.net
authors.forename: Kazumi
authors.initials: K
authors.lastname: Uchida
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Hayashi
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Kuramochi
authors.forename: Go
authors.initials: G
authors.lastname: Nakajima
authors.forename: Yuji
authors.initials: Y
authors.lastname: Inoue
authors.forename: Masakazu
authors.initials: M
authors.lastname: Yamamoto
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin